Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15330176 | 0.88 | MGLL (0.43) | ENPP2MGLLCA1CA2RXRA | |
| SCHEMBL2554931 | 0.81 | MAOB (0.45) | ENPP2MGLLCA1CA2RAB9A | |
| SCHEMBL29950784 | 0.81 | RXRA (0.47) | MGLLRXRARXRBRXRGALDH1A1 | |
| SCHEMBL12260219 | 0.81 | RXRA (0.47) | MGLLRXRARXRBRXRGALDH1A1 | |
| SCHEMBL29954385 | 0.81 | MGLL (0.43) | ENPP2MGLLCYP3A4ALDH1A1ORAI1 | |
| SCHEMBL8830 | 0.80 | ENPP2 (0.61) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL16164272 | 0.80 | MGLL (0.61) | MGLLRXRARXRBRXRGORAI1 | |
| SCHEMBL5782136 | 0.80 | ALDH1A1 (0.58) | CA1CA2RXRARXRBRXRG | |
| SCHEMBL679095 | 0.80 | ALDH1A1 (0.50) | CA1CA2RXRARXRBRXRG | |
| SCHEMBL126169 | 0.80 | MGLL (0.61) | MGLLRXRARXRBRXRGP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| WO-2025215450-A1 | THIAZOLE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-16 | — | — | WO | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| EP-3365335-B1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230416202-A1 | Small Molecule Compounds and Compositions | TELO THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| EP-4247374-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | Telo Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116710431-A | Small molecule compounds and compositions | 泰洛治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2804747-B1 | OPTICAL ARTICLE AND METHOD OF FORMING | DDP SPECIALTY ELECTRONIC MAT US 9 LLC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | ENPP2 350/4885MGLL 400/4885CA1 4760/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | ENPP2 1629/4885MGLL 2834/4885CA1 976/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ENPP2 36/4885MGLL 15/4885CA1 908/4885 |
| US-20230416202-A1 | Small Molecule Compounds and Compositions | TERT, TP53, EP300 | ENPP2 3991/4885MGLL 3812/4885CA1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.